Because revenue held near $970M while gross profit fell to $47M, the compression cannot be explained by lower plant absorption; it more likely reflects input cost inflation in semiconductors and engineering labor failing to pass through contractual price adjustments, which typically lag by several quarters. The 2024Q4 net margin of 13.0% now looks like a non-recurring high-water mark rather than a run-rate, since it was accompanied by a 17.3% FCF margin that has since inverted to negative 0.4%. For true earning power, investors should anchor to the 8-10% operating margin band Visteon sustained through 2025 and ask whether the pass-through mechanism can restore it, rather than extrapolating the 0.1% trough or the 2024 spike.

The efficiency component of the decay deserves as much attention as the margin component: asset turnover has fallen in eight of ten quarters, which implies either an asset base inflated by pre-launch inventory and capitalized program costs, or revenue that is failing to scale against that base. ROE of 0.3% against ROIC of 0.1% indicates virtually no leverage benefit is being captured, which is unsurprising given the near-zero earnings denominator. If ROIC does not recover toward the 5-6% range Visteon posted in 2024-2025, the case for the company as a capital-light compute integrator rather than a build-to-print hardware supplier weakens considerably.

DSO has been remarkably stable in the 63-73 day band and DIO in the 31-36 day band throughout the period, meaning the working capital story is one of supplier financing, not operating discipline — and supplier terms that lengthen during a margin downturn may signal Visteon's own vendors repricing risk. The parallel draw on liquidity is notable: the prior cash flow work shows working capital consumed $133M over the last four quarters, which sits awkwardly alongside a CCC that appears to be improving. Analysts should treat the headline CCC improvement as borrowed time rather than genuine efficiency until DSO or DIO move.

The covenant and refinancing risk on the $459M debt stack appears modest in isolation, and the current ratio of 1.61 with a 1.27 quick ratio suggests inventory is not the dominant component of near-term liquidity. However, the combination of falling cash (to $464M from a $771M peak) and a $200M buyback executed in a negative-FCF quarter means the balance sheet is being managed more aggressively than the earnings profile would ordinarily justify, in my view. Investors should monitor whether the debt/EBITDA multiple, now at 14.34x on a deflated EBITDA base, normalizes through earnings recovery or forces a recalibration of capital return.

The forward EV/EBITDA of 4.73x trading above the trailing 4.08x is the tell: the market is pricing in an EBITDA recovery, and the trailing multiple is therefore flattered rather than conservative. Against peers, Visteon's 0.31 D/E and 0.54x sales should command a premium on balance sheet quality, but Lear at 1.20x book with a 9.7% ROIC highlights that the market pays for returns, not for cash. The P/S of 0.54x looks like deep value only if one assumes the 4.8% gross margin is cyclical; if it reflects structurally weaker pricing power against Chinese NEV customers and OEM insourcing, the multiple is closer to fair.